Alpelisib(CAS: 1217486-61-7)

Alpelisib (CAS: 1217486-61-7) is regulated under the Globally Harmonized System of Classification and Labelling of Chemicals (GHS) for its physical and health hazards. In the European Union, it falls under REACH regulations. For FDA/EPA compliance, it is important to adhere to the specific guidelines for pharmaceuticals and chemical substances, including proper labeling, storage, and handling to prevent environmental contamination.

Alternative reagents to Alpelisib (CAS: 1217486-61-7) in synthesis include similar phosphoinositide 3-kinase inhibitors such as copanlisib and pictilisib. These compounds can be used as analogs in various synthetic pathways, offering similar pharmacological effects but with different chemical structures.

Alpelisib (CAS: 1217486-61-7) has a growing market trend, particularly in oncology due to its role as a selective phosphoinositide 3-kinase (PI3K) inhibitor. Research is expanding into new clinical trials and studies, focusing on its efficacy in treating certain types of breast and ovarian cancer. Market trends indicate increasing demand as more therapeutic applications are explored.

Waste containing Alpelisib (CAS: 1217486-61-7) should be collected in appropriate containers, labeled, and stored in a secure area to prevent environmental contamination. Proper disposal methods include incineration or professional waste disposal services that comply with local regulations. Environmental precautions include monitoring for any leakage and ensuring all waste is treated before disposal to minimize ecological impact.